Alkermes plc. market cap ALKS

Share price times shares outstanding: what the whole company sells for, since 2011.

Alkermes plc. is worth $7.3B at the close on Oct 23, 2026, at $43.63 a share.

That is up 49% over the last year and up 49% over five years.

Its highest close in our data was $11.9B in Dec 2015.

Market cap over time

Year	End of year	Low	High	Change
2026 so far	$7.3B	$4.6B	$9.2B	+56%
2025	$4.7B	$4.3B	$5.8B	−2%
2024	$4.8B	$4B	$5.4B	+3%
2023	$4.6B	$4B	$5.5B	+8%
2022	$4.3B	$3.6B	$5.2B	+14%
2021	$3.8B	$3B	$5.2B	+18%
2020	$3.2B	$2.1B	$3.5B	−1%
2019	$3.2B	$2.8B	$5.8B	−27%
2018	$4.4B	$4.4B	$10.5B	−47%
2017	$8.4B	$7.4B	$9.4B	−0%
2016	$8.4B	$4.6B	$10.7B	−29%
2015	$11.9B	$8.5B	$11.9B	+41%
2014	$8.4B	$5.5B	$8.6B	+51%
2013	$5.6B	$2.7B	$5.6B	+128%
2012	$2.4B	$2B	$2.7B	+9%
2011	$2.2B	$1.8B	$2.3B	n/a

Companies in Drug Manufacturers - General nearest Alkermes plc.'s size, closest first, today.

Company	Market cap
ALKSAlkermes plc.	$7.3B
AMRXAmneal Pharmaceuticals	$6.5B
TGTXTG Therapeutics	$8.3B
LGNDLigand Pharmaceuticals	$6.1B
KNSAKiniksa Pharmaceuticals International	$6B
PTGXProtagonist Therapeutics	$9B
CORTCorcept Therapeutics	$9.3B
BMRNBiomarin Pharmaceutical	$10.8B
INDVIndivior Pharmaceuticals	$4.1B
ARQTArcutis Biotherapeutics	$3.9B
JAZZJazz Pharmaceuticals	$13.9B
Peer median	$7.4B